Shots:

• The NMPA has approved the IND application to initiate the P-I trial of ASC11 (3CLpro inhibitor) for COVID-19. The trial is expected to be completed in Q1’23
• The objective of the trial is to identify a safe and efficacious dose for the P-II/III trial in COVID-19 patients & will also identify whether ASC11 needs to be boosted by ritonavir or not
• In antiviral cellular assays, the therapy showed a higher potency against SARS-CoV-2 over 3CLpro inhibitors incl. Nirmatrelvir, S-217622, PBI-0451 & EDP-235 and also showed potent antiviral activity against multiple popular Omicron variants incl. BA.1 and BA.5 along with potent antiviral activity in the animal model

Ref: PRNewswire | Image: Ascletis